Identification of sentinel lymph node with infrared fluorescence in lung cancer

Identification of sentinel lymph node with infrared fluorescence in lung cancer - Identification of sentinel lymph node in lung cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000026155

Enrollment

150

Registered

2017-03-21

Start date

2017-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

lung cancer

Interventions

When we would reach thoracic cavity at usual lung cancer operation, we identify the location of tumors. we would inject 0.5ml of ICG to the normal lung parenchyma around tumor.Sentinel lymph node woul

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: primary lung cancer patient with clinical stage I according to preoperative examination.

Exclusion criteria

Exclusion criteria: The patient without tolerance for segmentectomy.

Design outcomes

Primary

Measure	Time frame
Primary endpoint is to assess sensitivity and specificity of sentinel lymph node identification. Standard operation for lung cancer (lobectomy and lymph node dissection) would be performed, and compare metastatic status of sentinel lymph node with that of the other mediastinal lymph node by postoperative histopathological examination.	—

Secondary

Measure	Time frame
To assess adverse effect for local injection of ICG.	—

Countries

Japan

Contacts

Public ContactHiromitsu Takizawa

Institute of Biomedical Sciences, Tokushima University Graduate School Department of Thoracic,Endocrine Surgery and Oncology

h-takizawa@mbf.ocn.ne.jp088-633-7143

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026